Takeda Pharmaceutical
339 hedge funds and large institutions have $2.53B invested in Takeda Pharmaceutical in 2019 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 86 increasing their positions, 104 reducing their positions, and 38 closing their positions.
71% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 38
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
7% more funds holding
Funds holding: 317 → 339 (+22)
3% more capital invested
Capital invested by funds: $2.45B → $2.53B (+$74.7M)
3% more call options, than puts
Call options by funds: $95.2M | Put options by funds: $92.8M
0.81% less ownership
Funds ownership: 9.06% → 8.24% (-0.81%)
17% less repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 104
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
+$60.1M |
| 2 |
RA
Rovida Advisors
Fort Lauderdale,
Florida
|
+$22.1M |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$6.53M |
| 4 |
Millennium Management
New York
|
+$6.45M |
| 5 |
Renaissance Technologies
New York
|
+$5.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$162M |
| 2 |
HI
HBK Investments
Dallas,
Texas
|
-$45.4M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$35.7M |
| 4 |
D.E. Shaw & Co
New York
|
-$28M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$15.7M |
TAK Hedge Fund Activity: Q4 2019 in Review
339 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2019, worth a combined $2.53B — up 3% from $2.45B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new TAK positions and 38 closed out — a net gain of 27 holders — while 86 added to existing stakes and 104 trimmed.
The largest buyer was Glenview Capital Management, adding an estimated $60.1M. The largest seller was Baupost Group, exiting entirely with an estimated $162M sold.
- 339 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2019, up from 317 in Q3 2019.
- Funds reported $2.53B of Takeda Pharmaceutical stock for Q4 2019, up 3% quarter-over-quarter.
- 65 funds opened new Takeda Pharmaceutical positions in Q4 2019 and 38 closed out, a net change of +27 holders.
- The largest Takeda Pharmaceutical buyer in Q4 2019 was Glenview Capital Management, an estimated $60.1M added.
- The largest Takeda Pharmaceutical seller in Q4 2019 was Baupost Group, an estimated $162M sold.
Based on aggregated 13F filings for Q4 2019.